Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2006-11-14
2006-11-14
Nguyen, Dave Trong (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000
Reexamination Certificate
active
07135610
ABSTRACT:
A transgenic mouse transformed with a DNA encoding a mutant human tau protein, wherein the mouse exhibits neurofibrillary tangles in its brain. The transgenic mouse is useful for the development of the agent for treating neurodegenerative disorders such as Alzheimer's disease.
REFERENCES:
patent: 6593512 (2003-07-01), Vitek et al.
patent: WO 99/57129 (1999-11-01), None
patent: WO 99/62548 (1999-12-01), None
patent: WO-01/53340 (2001-07-01), None
Brion JP, Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in te pretangle stage of Alzheimer's disease, 1999, vol. 154, pp. 255-270.
Sasahara M, PDGF B-chain in neurons of the central nervous system, posterior pituitary, and in a transgenic model, 1991, Cell, vol. 64, pp. 217-227.
Games D, Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, 1995, Nature, vol. 373, pp. 523-527.
Gotz J, Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform, 1995, EMBO Journal, vol. 14, pp. 1304-1313.
Ishihara T, Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform, 1999, Neuron, vol. 24, pp. 751-762.
Nacharaju P, Accelerated filament formation from tau protein with specific FTDP-17 missense mutations, 1999, FEBS Letters, vol. 447, pp. 195-199.
Voglesbersg-Ragaglia V, Distinct FTDP-17 Missense Mutations in Tau Produce Tau aggregates and other pathological phenotypes in transfected CHO cells, 2000, Mol. Biol. Cell, vol. 11, pp. 4093-4104.
Sahara N, Missense point mutations of Tau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: a novel action of R406W mutation, 2000, J. Neuroscience Res., vol. 60, pp. 380-387.
T. Frappier et al., FEBS Letters 455 (3) :262-266 (1999).
A. Takashima et al., “Characterization of transgenic mice expressing V377M human tau”, Society for Neuroscience Abstracts, vol. 26, No. 1-2, Abstract No. 202.5; 30thannual meeting of the Society of Neuroscience; New Orleans, LA, Nov. 4-9, 2000, XP002298080 (abstract).
Spittaels K. et al., American Journal of Pathology, vol. 155, 1999, pp. 2153-2165.
Hasegawa M. et al., FEBS. Letters, vol. 437, 1998, pp. 201-210.
Rockenstein E. W. et al., Journal of Biological Chemistry, vol. 270, 1997, pp. 28257-28267.
C. Zehr et al., Society for Neuroscience Abstracts, vol. 25, No. 1-2 (1999), p. 1097.
Irizarry et al., The Journal of Neuroscience, Vol. 17, No. 18 (1997), pp. 7053-7059.
Montanari David A.
Nguyen Dave Trong
Riken
LandOfFree
Mouse showing neurofibril change due to senile dementia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mouse showing neurofibril change due to senile dementia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mouse showing neurofibril change due to senile dementia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651454